--- title: "Korro Bio (KRRO) news: offering" url: "https://aibio.space/companies/korro-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KRRO offering news: Korro Bio agrees to $85 million private placement led by Venrock Healthcare. Korro Bio, Inc. (NASDAQ: KRRO), United States." --- KRRO Korro Bio, Inc. NASDAQ · United States # Korro Bio (KRRO) news KRRO offering news Financings · 2026-03-09 ## [Korro Bio agrees to $85 million private placement led by Venrock Healthcare](https://aibio.space/news/korro-bio-agrees-85-million-private-placement-led-venrock-healthcare/) Korro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028. ## Latest Korro Bio news 1. 2025-11-12 Distress [Korro Bio cuts approximately 34% of workforce in restructuring, pauses Novo Nordisk deal](https://aibio.space/news/korro-bio-cuts-approximately-34-percent-workforce-restructuring-pauses/) Korro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected. 2. 2025-11-12 Distress [Korro Bio cuts about 34% of workforce, expects cash runway into second half of 2027](https://aibio.space/news/korro-bio-cuts-about-34-percent-workforce-expects-cash-runway-second/) The RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels. 3. 2025-05-07 Distress [Korro Bio announces 20% workforce reduction, expects cash runway into 2027](https://aibio.space/news/korro-bio-announces-20-percent-workforce-reduction-expects-cash-runway/) Korro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter. 4. 2024-12-02 Financings [Korro Bio files $400,000,000 shelf with a $100,000,000 stock sales program](https://aibio.space/news/korro-bio-files-400-000-000-shelf-100-000-000-stock-sales-program/) Korro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance. ## Korro Bio at a glance - **Ticker**: KRRO - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $115.0 million ### Related companies - [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) NASDAQ: ZVRA - [Innovation Pharmaceuticals](https://aibio.space/companies/innovation-pharmaceuticals/) OTC: IPIX - [Moleculin Biotech](https://aibio.space/companies/moleculin-biotech/) NASDAQ: MBRX - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) NASDAQ: RLMD - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) NASDAQ: ATRA - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX ### Also on NASDAQ - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) AGIO - [IDEAYA Biosciences](https://aibio.space/companies/ideaya-biosciences/) IDYA - [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) ABOS - [RadNet](https://aibio.space/companies/radnet/) RDNT - [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) CUE - [Rein Therapeutics](https://aibio.space/companies/rein-therapeutics/) RNTX ## Korro Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | [$2.3 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | | Research and development | [$65.6 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | [$63.6 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | | Net income (loss) | [-$117.3 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | [-$83.6 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | | Cash from operations | [-$78.6 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | [-$60.1 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | | Cash and equivalents | [$21.8 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336707/) | [$55.6 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | | Short-term investments | [$53.3 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336707/) | [$70.5 million](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104156/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.9 million, plus short-term investments of $90.1 million, $115.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Korro Bio Has Korro Bio raised money recently? Our latest story on this, dated Mar 9, 2026: "Korro Bio agrees to $85 million private placement led by Venrock Healthcare". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/korro-bio-agrees-85-million-private-placement-led-venrock-healthcare/). What is the ticker symbol of Korro Bio? Korro Bio, Inc. trades under the ticker KRRO on NASDAQ. Where is Korro Bio listed? Korro Bio, Inc. is listed on NASDAQ. What is the SEC CIK of Korro Bio? The SEC Central Index Key (CIK) for Korro Bio, Inc. is 1703647. Its filings are on SEC EDGAR. How many shares does Korro Bio have outstanding? 14,725,646 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Korro Bio listed under? Our directory records Korro Bio, Inc. under United States. What does Korro Bio do? Our directory classifies Korro Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Korro Bio? The ISIN recorded for Korro Bio, Inc. is US5009461089. Does aibio.space cover Korro Bio? aibio.space lists Korro Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Korro Bio incorporated? SEC records list its state or country of incorporation as DE. What was Korro Bio's revenue last year? $6.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Korro Bio profitable? Korro Bio, Inc. reported a net loss of $117.3 million for the fiscal year ended Dec 31, 2025, and used $78.6 million of cash in operations, per its annual report to the SEC. How much does Korro Bio spend on research and development? $65.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Korro Bio have? $115.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Korro Bio (KRRO) stock news? Our latest story on Korro Bio, dated Mar 9, 2026: "Korro Bio agrees to $85 million private placement led by Venrock Healthcare". Korro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028. [Source](https://aibio.space/news/korro-bio-agrees-85-million-private-placement-led-venrock-healthcare/). ## Investor discussion: Korro Bio Members talk about Korro Bio (KRRO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Korro Bio, newest first. Each line links the filing it comes from. 1. 2026-08-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-ex99_1.htm) 2. 2026-03-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/krro-ex99_1.htm) 3. 2025-11-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.02,2.05,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1703647/000119312525277556/krro-ex99_1.htm) 4. 2025-05-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1703647/000095017025065786/krro-ex99_1.htm) 5. 2024-12-02 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1703647/000119312524268934/d854612ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KRRO on TradingView](https://www.tradingview.com/symbols/NASDAQ-KRRO/). ## SEC filings and registration - **SEC name**: Korro Bio, Inc. - **CIK**: 1703647 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KRRO (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 60 FIRST STREET, CAMBRIDGE, MA, 02141 - **Phone**: 617-468-1999 - **Shares outstanding**: 14,725,646 as of 2026-08-05 (10-Q filed 2026-08-06) - **Former names**: Frequency Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526428306/krro-20261022.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526414118/krro-20261005.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm) filed 2026-08-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336707/krro-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-20260805.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526267741/krro-20260610.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/krro-20260519.htm) filed 2026-05-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1703647/000119312526210303/krro-20260331.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001703647), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Korro Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KRRO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Korro Bio, Inc. - **Ticker**: KRRO - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US5009461089 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KRRO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/korro-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Korro Bio (KRRO) news: offering", 2026-10-31, https://aibio.space/companies/korro-bio/